Pulmonary biopsy is commonly performed for the diagnosis of interstitial pulmonary disease. The lingula has technical advantages on account of which it is frequently used. The quality of this tissue is however discutable. The authors submit a retrospective five-year group of 80 patients operated at the Surgical Clinic of the Faculty Hospital Plzen 53 times videothoracoscopically (66.2%) and 27 times by limited thoracotomy (33.8%). Both methods are in the authors opinion sufficiently effective to obtain bioptic material. The guide for localization of the biopsy is computed tomography. Only once from a total of 38 samples (2.6%) collected from the lingula an unequivocal diagnosis was not established. The authors assume therefore that pulmonary biopsy collected from the lingula is still justified.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparison of Early Functional Recovery Following Triportal Robot-Assisted and Uniportal Video-Assisted Segmentectomy in Patients With Early-Stage Non-Small Cell Lung Cancer: A Propensity Score-Matched Analysis.
Thorac Cancer
March 2025
Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong First Medical University, Jinan, P. R. China.
Background: Robot-assisted thoracoscopic surgery (RATS) is more precise and flexible than video-assisted thoracoscopic surgery (VATS) for early-stage non-small cell lung cancer (NSCLC) treatment. This study compared the early postoperative functional recovery of patients who underwent triportal RATS with that of patients who underwent uniportal video-assisted thoracic surgery (UVATS) for segmentectomy.
Methods: This observational, prospective study included 172 patients with clinical stage I or II peripheral NSCLC who underwent RATS or UVATS segmentectomy.
Online monitoring and stable isotope tracing of cancer associated volatiles in murine model captures tumor associated markers in vivo.
Anal Chim Acta
May 2025
Department of Human Sciences, The Ohio State University, USA; James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA. Electronic address:
Background: The imperative need for early cancer detection, which is crucial for improved survival rates in many severe cancers such as lung cancer, remains challenging due to the lack of reliable early-diagnosis technologies and robust biomarkers. To address this gap, innovative screening platforms are essential to unveil the chemical signatures of lung cancer and its treatments. It is established that the oxidative tumor environment induces alterations in host metabolic processes and influences endogenous volatile synthesis.
View Article and Find Full Text PDFAssociation of ceramide risk scores with rheumatoid arthritis: a FINRISK population-based cohort study.
BMJ Open
March 2025
Zora Biosciences Oy, Espoo, Finland
Objectives: This study aimed to explore the association between lipid-based Cardiovascular Event Risk Tests (CERT1 and CERT2), including ceramides (Cer) and phosphatidylcholine (PC) lipid species, and rheumatoid arthritis (RA), an inflammatory disease that can increase the risk of cardiovascular diseases.
Design: Prospective population-based cohort study.
Setting: Primary care centres across five geographical areas in Finland.
[A Case of Successful Hepatic Resection of Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab for Recurrent Liver and Lung Metastases].
Gan To Kagaku Ryoho
February 2025
Dept. of General Surgery, Graduate School of Medicine, Chiba University.
Drug therapy for hepatocellular carcinoma has made remarkable progress in recent years, and surgical resection of tumors that respond well to drug therapy has been performed in some cases. We report a case of hepatocellular carcinoma with hepatopulmonary metastases that was successfully treated with atezolizumab plus bevacizumab and surgically resected. The patient was a 56-year-old man who underwent a posterior segmentectomy and was diagnosed with hepatocellular carcinoma.
View Article and Find Full Text PDFThe novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosis.
J Pharmacol Exp Ther
February 2025
Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Pulmonary fibrosis encompasses different chronic interstitial lung diseases, and the predominant form, idiopathic pulmonary fibrosis, remains to have a poor prognosis despite 2 approved therapies. Although the exact pathobiological mechanisms are still incompletely understood, epithelial injury and aberrant wound healing responses contribute to the gradual change in lung architecture and functional impairment. Lysophosphatidic acid (LPA)-induced lysophosphatidic receptor 1 (LPA1) signaling was proposed to be a driver of lung fibrosis, and LPA1 antagonists have shown promising antifibrotic profiles in early clinical development.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!